Inactive Instrument

Oncothyreon Inc (USA) Share Price Nasdaq

Equities

Duration

Period

Style

Cascadian Therapeutics Announces 2018 Outlook and Recent Progress	04/18/04	GL
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency	02/18/02	GL
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index	13/17/13	GL
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer	08/17/08	GL
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results	09/17/09	GL

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B